

Ashwin Ananthakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6910490/publications.pdf>

Version: 2024-02-01

294
papers

25,611
citations

11651

70
h-index

8167

148
g-index

320
all docs

320
docs citations

320
times ranked

29720
citing authors

#	ARTICLE	IF	CITATIONS
1	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
2	Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 2019, 569, 655-662.	27.8	1,638
3	Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. American Journal of Gastroenterology, 2013, 108, 478-498.	0.4	1,413
4	Epidemiology and risk factors for IBD. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 205-217.	17.8	1,202
5	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.4	933
6	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell, 2019, 178, 714-730.e22.	28.9	806
7	Environmental triggers in IBD: a review of progress and evidence. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 39-49.	17.8	573
8	A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology, 2013, 145, 970-977.	1.3	494
9	Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nature Microbiology, 2018, 3, 337-346.	13.3	408
10	Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut, 2014, 63, 776-784.	12.1	386
11	Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut, 2008, 57, 205-210.	12.1	364
12	Clostridium difficile infection: epidemiology, risk factors and management. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 17-26.	17.8	313
13	Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host and Microbe, 2017, 21, 603-610.e3.	11.0	306
14	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Alimentary Pharmacology and Therapeutics, 2017, 45, 1291-1302.	3.7	230
15	Development of phenotype algorithms using electronic medical records and incorporating natural language processing. BMJ, The, 2015, 350, h1885-h1885.	6.0	226
16	Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis. Annals of Internal Medicine, 2012, 156, 350.	3.9	223
17	Sleep Disturbance and Risk of Active Disease in Patients With Crohn's Disease and Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2013, 11, 965-971.	4.4	192
18	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. Nature Communications, 2018, 9, 3347.	12.8	192

#	ARTICLE	IF	CITATIONS
19	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 3-13.	3.7	190
20	Geographical variation and incidence of inflammatory bowel disease among US women. <i>Cut</i> , 2012, 61, 1686-1692.	12.1	187
21	Review article: vitamin D and inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 125-136.	3.7	181
22	The role of diet in the aetiopathogenesis of inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 525-535.	17.8	178
23	Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 182-189.	1.9	175
24	Normalization of Plasma 25-Hydroxy Vitamin D Is Associated with Reduced Risk of Surgery in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	168
25	Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 780-789.	3.7	163
26	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	4.4	161
27	Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 107-112.	1.3	155
28	Outcomes of Weekend Admissions for Upper Gastrointestinal Hemorrhage: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 296-302.e1.	4.4	153
29	Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1252-1260.	4.4	153
30	Epidemiology of Primary and Secondary Liver Cancers. <i>Seminars in Interventional Radiology</i> , 2006, 23, 047-063.	0.8	150
31	Improving Case Definition of Crohn's Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1411-1420.	1.9	142
32	Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 269-276.	8.1	139
33	Fatigue in IBD: epidemiology, pathophysiology and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 247-259.	17.8	137
34	Environmental Risk Factors for Inflammatory Bowel Diseases: A Review. <i>Digestive Diseases and Sciences</i> , 2015, 60, 290-298.	2.3	136
35	Temporal trends in disease outcomes related to <i>Clostridium difficile</i> infection in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 976-983.	1.9	130
36	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis. Clinical Infectious Diseases, 2014, 58, 1507-1514.	5.8	128
38	Ambient air pollution correlates with hospitalizations for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1138-1145.	1.9	127
39	Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 309-315.	1.9	127
40	Association Between Depressive Symptoms and Incidence of Crohn's Disease and Ulcerative Colitis: Results From the Nurses' Health Study. Clinical Gastroenterology and Hepatology, 2013, 11, 57-62.	4.4	123
41	Measures of Obesity and Risk of Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 361-368.	1.9	123
42	Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 1224-1236.	1.3	122
43	Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 645-656.	3.7	121
44	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 151, 97-109.e4.	1.3	120
45	Disparities in Colon Cancer Screening in the Medicare Population. Archives of Internal Medicine, 2007, 167, 258.	3.8	117
46	Does It Matter Where You Are Hospitalized for Inflammatory Bowel Disease? A Nationwide Analysis of Hospital Volume. American Journal of Gastroenterology, 2008, 103, 2789-2798.	0.4	115
47	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology, 2016, 151, 724-732.	1.3	109
48	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clinical Gastroenterology and Hepatology, 2020, 18, 14-23.	4.4	108
49	Colonoscopy Is Associated With a Reduced Risk for Colon Cancer and Mortality in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2015, 13, 322-329.e1.	4.4	107
50	Psychiatric comorbidity is associated with increased risk of surgery in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 445-454.	3.7	101
51	Association Between Reduced Plasma 25-Hydroxy Vitamin D and Increased Risk of Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2014, 12, 821-827.	4.4	101
52	Pretreatment 25-Hydroxyvitamin D Levels and Durability of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases. Journal of Parenteral and Enteral Nutrition, 2014, 38, 385-391.	2.6	98
53	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clinical Gastroenterology and Hepatology, 2018, 16, 99-105.	4.4	97
54	Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology, 2020, 159, 873-883.e1.	1.3	96

#	ARTICLE	IF	CITATIONS
55	High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). <i>Nature Protocols</i> , 2019, 14, 3426-3444.	12.0	94
56	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 58-64.	4.4	93
57	Environmental Triggers for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2013, 15, 302.	2.5	91
58	Permanent Work Disability in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 154-161.	0.4	90
59	Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. <i>Cell Host and Microbe</i> , 2021, 29, 1294-1304.e4.	11.0	85
60	Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 190-197.e11.	4.4	84
61	The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. <i>ELife</i> , 2019, 8, .	6.0	84
62	Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. <i>International Journal of Epidemiology</i> , 2015, 44, 1995-2005.	1.9	83
63	Enabling phenotypic big data with PheNorm. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 54-60.	4.4	82
64	Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts. <i>PLoS ONE</i> , 2015, 10, e0136651.	2.5	82
65	Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2020, 158, 2104-2111.e2.	1.3	81
66	High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	80
67	Pivot to Asia: inflammatory bowel disease burden. <i>Intestinal Research</i> , 2017, 15, 138.	2.6	80
68	Predictors of severe outcomes associated with <i>Clostridium difficile</i> infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 789-795.	3.7	79
69	Differential Effect of Genetic Burden on Disease Phenotypes in Crohn's Disease and Ulcerative Colitis: Analysis of a North American Cohort. <i>American Journal of Gastroenterology</i> , 2014, 109, 395-400.	0.4	77
70	The emergence of <i>Clostridium difficile</i> infection in Asia: A systematic review and meta-analysis of incidence and impact. <i>PLoS ONE</i> , 2017, 12, e0176797.	2.5	77
71	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1879-1886.	4.4	76
72	Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1736-1743.e4.	4.4	76

#	ARTICLE	IF	CITATIONS
73	Comparative safety and effectiveness of tumor necrosis factor \pm antagonists and vedolizumab in elderly IBD patients: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 873-879.	3.7	76
74	Management of Inflammatory Bowel Disease in the Elderly Patient. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 882-893.	1.9	75
75	Racial Differences in Liver Transplantation Outcomes in the MELD Era. <i>American Journal of Gastroenterology</i> , 2008, 103, 901-910.	0.4	72
76	Similar Risk of Depression and Anxiety Following Surgery or Hospitalization for Crohn's Disease and Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2013, 108, 594-601.	0.4	72
77	Deep Vein Thrombosis and Pulmonary Embolism in Hospitalized Patients with Cirrhosis: A Nationwide Analysis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2152-2159.	2.3	71
78	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1800-1813.e4.	4.4	70
79	Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 502-509.e1.	4.4	69
80	Surrogate-assisted feature extraction for high-throughput phenotyping. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e143-e149.	4.4	68
81	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 176-181.	1.9	67
82	<i>Clostridium difficile</i> associated risk of death score (<scp>CARDS</scp>): a novel severity score to predict mortality among hospitalised patients with <i>C. difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 725-733.	3.7	65
83	Environmental Hygiene and Risk of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2191-2199.	1.9	63
84	Diet in Treatment of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 425-435.e3.	4.4	63
85	A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 267-276.	1.7	62
86	Thromboprophylaxis Is Associated With Reduced Post-hospitalization Venous Thromboembolic Events in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1905-1910.	4.4	61
87	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 818-824.e6.	4.4	61
88	Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer. <i>Journal of General Internal Medicine</i> , 2010, 25, 1164-1171.	2.6	60
89	Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1323-e1337.	4.4	60
90	<i>Clostridium Difficile</i> and Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 711-728.	2.2	59

#	ARTICLE	IF	CITATIONS
91	Higher plasma vitamin D is associated with reduced risk of <i>Clostridium difficile</i> infection in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1136-1142.	3.7	56
92	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 973-979.	4.4	56
93	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1590-1596.	2.3	56
94	Severe Pulmonary Toxicity After Azathioprine/6-Mercaptopurine Initiation for the Treatment of Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 682-688.	2.2	55
95	A Novel Risk Score to Stratify Severity of Crohn's Disease Hospitalizations. <i>American Journal of Gastroenterology</i> , 2010, 105, 1799-1807.	0.4	55
96	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1366-1376.e2.	4.4	55
97	New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 972-979.	3.7	52
98	Early Life Factors and Risk of Inflammatory Bowel Disease in Adulthood. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 542-547.	1.9	50
99	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016, 7, 12342.	12.8	50
100	Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 347-355.	3.7	50
101	Genetic risk factors for <i>Clostridium difficile</i> infection in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 522-530.	3.7	49
102	Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 956-963.	1.3	49
103	Caroli's disease: Identification and treatment strategy. <i>Current Gastroenterology Reports</i> , 2007, 9, 151-155.	2.5	48
104	Trends in Ambulatory and Emergency Room Visits for Inflammatory Bowel Diseases in the United States: 1994-2005. <i>American Journal of Gastroenterology</i> , 2010, 105, 363-370.	0.4	48
105	Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 459-466.	3.7	48
106	Impact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2013, 108, 1123-1129.	0.4	48
107	A Comprehensive Study of Costs Associated With Recurrent <i>Clostridium difficile</i> Infection. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 196-202.	1.8	48
108	Cancer risk in microscopic colitis: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2019, 19, 1.	2.0	48

#	ARTICLE	IF	CITATIONS
109	Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 155-161.	1.9	48
110	Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1197-1200.	4.4	47
111	Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 87-95.e4.	4.4	47
112	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 845-851.	1.3	46
113	Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	45
114	High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2136-2143.	2.3	45
115	Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2017, 62, 197-206.	2.3	45
116	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2009-2017.	0.4	44
117	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 880-885.	1.9	44
118	Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 37-44.	1.9	43
119	Interobserver Agreement for the Detection of Barrett's Esophagus with Optical Frequency Domain Imaging. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2261-2265.	2.3	43
120	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1133-1141.e3.	4.4	43
121	Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2016, 7, 554.	4.8	42
122	Clostridium Difficile and Inflammatory Bowel Disease. <i>Medical Clinics of North America</i> , 2010, 94, 135-153.	2.5	40
123	Frailty is independently associated with mortality in 11,001 patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 311-318.	3.7	40
124	Serum Inflammatory Markers and Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1342-1348.e1.	4.4	38
125	Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1141-1148.	3.7	38
126	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4178-4190.	2.3	38

#	ARTICLE	IF	CITATIONS
127	Simple score to identify colectomy risk in ulcerative colitis hospitalizations. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1532-1540.	1.9	37
128	Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. <i>Scientific Reports</i> , 2018, 8, 12699.	3.3	37
129	Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 340-349.	0.4	37
130	<scp>HBV</scp>/<scp>HIV</scp> coinfection is associated with poorer outcomes in hospitalized patients with <scp>HBV</scp> or <scp>HIV</scp>. <i>Journal of Viral Hepatitis</i> , 2016, 23, 820-829.	2.0	36
131	Multi-â€œOmicsâ€œProfiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1524-1532.	1.9	36
132	Weekend hospitalisations and postâ€œoperative complications following urgent surgery for ulcerative colitis and <scp>C</scp>ohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 895-904.	3.7	35
133	Treatment of Ulcerative Colitis in the Elderly. <i>Digestive Diseases</i> , 2009, 27, 327-334.	1.9	34
134	Early life environment and natural history of inflammatory bowel diseases. <i>BMC Gastroenterology</i> , 2014, 14, 216.	2.0	34
135	Genetic Polymorphisms in Metabolizing Enzymes Modifying the Association Between Smoking and Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 783-789.	1.9	34
136	Genetic Markers Predict Primary Nonresponse and Durable Response to Antiâ€œTumor Necrosis Factor Therapy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1840-1848.	1.9	34
137	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 447-470.	1.4	34
138	The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn's Disease in Children. <i>American Journal of Gastroenterology</i> , 2018, 113, 1524-1529.	0.4	33
139	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. <i>Gastroenterology</i> , 2021, 160, 445-451.	1.3	33
140	Dyssynergic Defecation: A Treatable Cause of Persistent Symptoms When Inflammatory Bowel Disease Is in Remission. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3600-3605.	2.3	32
141	Impact of<i>Clostridium difficile</i> on inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 589-600.	3.0	31
142	The impact of coâ€œexisting immuneâ€œmediated diseases on phenotype and outcomes in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 814-823.	3.7	31
143	Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 559-567.	1.3	31
144	â€œWeekend Effectâ€œin Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, 13-21.	0.4	31

#	ARTICLE	IF	CITATIONS
145	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 309-315.	1.3	31
146	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 519-527.e5.	4.4	31
147	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 666-678.	8.1	31
148	Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 339-353.	2.2	30
149	Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2507-2514.	1.9	30
150	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , 2016, 86, 62-70.	3.3	30
151	Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary n3. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1898-1904.	1.9	30
152	Economic burden and cost-effectiveness of therapies for Clostridioides difficile infection: a narrative review. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110186.	3.2	30
153	Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1088-1095.	1.9	29
154	Effect of hospital volume and teaching status on outcomes of acute liver failure. <i>Liver Transplantation</i> , 2008, 14, 1347-1356.	2.4	28
155	Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. <i>International Journal of Colorectal Disease</i> , 2019, 34, 491-499.	2.2	28
156	Mode of Childbirth and Long-Term Outcomes in Women with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2015, 60, 471-477.	2.3	27
157	Modifiable Environmental Factors in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2017, 19, 21.	2.5	27
158	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	4.4	27
159	The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 754-769.	8.1	27
160	Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 779-786.	1.9	26
161	Impact of Autonomic Dysfunction on Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 272-279.	2.2	25
162	Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 939-946.e4.	4.4	25

#	ARTICLE	IF	CITATIONS
163	Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 422-432.	1.0	24
164	Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 494-500.	1.9	24
165	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis—Results From the Nurses’ Health Study. <i>Gastroenterology</i> , 2018, 155, 1764-1775.e2.	1.3	24
166	Treatment of Intra-Abdominal Abscesses in Crohn’s Disease: A Nationwide Analysis of Patterns and Outcomes of Care. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2013-2018.	2.3	23
167	Metagenomic Characterization of Microbial Communities In Situ Within the Deeper Layers of the Ileum in Crohn’s Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 563-566.e5.	4.5	23
168	The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2242-2246.	1.9	23
169	Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2350-2359.	1.9	23
170	Reply to “Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients”. <i>Journal of Crohn’s and Colitis</i> , 2018, 12, 1256-1256.	1.3	23
171	Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Journal of Crohn’s and Colitis</i> , 2018, 12, 1036-1041.	1.3	23
172	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. <i>Advances in Therapy</i> , 2019, 36, 3079-3095.	2.9	23
173	Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1926-1932.	1.9	23
174	Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 88-95.	4.4	23
175	Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 52-60.	3.7	22
176	Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. <i>Journal of Crohn’s and Colitis</i> , 2018, 12, 525-531.	1.3	22
177	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	4.4	22
178	Frailty in inflammatory bowel diseases: an emerging concept. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110254.	3.2	22
179	Laparoscopic Resection for Inflammatory Bowel Disease: Outcomes from a Nationwide Sample. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 58-65.	1.7	21
180	Evaluation of matched control algorithms in EHR-based phenotyping studies: A case study of inflammatory bowel disease comorbidities. <i>Journal of Biomedical Informatics</i> , 2014, 52, 105-111.	4.3	21

#	ARTICLE	IF	CITATIONS
181	Asians Have More Perianal Crohn Disease and Ocular Manifestations Compared with White Americans. Inflammatory Intestinal Diseases, 2017, 2, 147-153.	1.9	21
182	Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1541-1543.	1.9	21
183	Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. Clinical Gastroenterology and Hepatology, 2022, 20, 1299-1305.e5.	4.4	21
184	Fracture-Associated Hospitalizations in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2011, 56, 176-182.	2.3	20
185	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2634-2640.	1.9	20
186	Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence. Digestive Diseases and Sciences, 2020, 65, 111-118.	2.3	20
187	Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV. Journal of Viral Hepatitis, 2010, 17, 720-729.	2.0	19
188	IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2247-2257.	1.9	19
189	Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. Digestive Diseases and Sciences, 2022, 67, 622-628.	2.3	19
190	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Digestive Diseases and Sciences, 2012, 57, 472-480.	2.3	18
191	The Doctor Will Call You Now! Telemedicine in the Midst of a Pandemic. Clinical Gastroenterology and Hepatology, 2020, 18, 1688-1690.	4.4	18
192	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	8.1	18
193	Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. Inflammatory Bowel Diseases, 2016, 22, 151-158.	1.9	16
194	Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset. Inflammatory Bowel Diseases, 2017, 23, 1187-1194.	1.9	16
195	Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. Digestive Diseases and Sciences, 2018, 63, 738-745.	2.3	16
196	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 872-880.e1.	4.4	16
197	Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 598-607.	3.7	16
198	Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case-control study. BMC Infectious Diseases, 2014, 14, 661.	2.9	15

#	ARTICLE	IF	CITATIONS
199	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2627-2635.	2.3	15
200	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1173-1182.	3.0	15
201	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 162-168.	3.7	15
202	Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 72-82.	0.1	15
203	Sugars and Gastrointestinal Health. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1912-1924.e7.	4.4	15
204	How Does Genotype Influence Disease Phenotype in Inflammatory Bowel Disease?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	14
205	Association Between Vulvovaginal Discomfort and Activity of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 604-611.e1.	4.4	14
206	Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2366-2372.e6.	4.4	14
207	Effect of oral tobacco use and smoking on outcomes of Crohn's disease in India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 134-140.	2.8	13
208	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Crohn's & Colitis</i> 360, 2019, 1, otz009.	1.1	13
209	Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2445-2450.	2.3	12
210	A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 760-767.	2.3	12
211	Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1226-1233.e1.	4.4	12
212	Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1740-1746.	1.9	12
213	Personalizing therapy for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 549-558.	3.0	10
214	Chromoendoscopy Is Better: So Why Am I Not (yet) Using it for Routine Inflammatory Bowel Disease Surveillance?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 720-722.	4.4	10
215	Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. <i>American Journal of Medicine</i> , 2016, 129, 628-634.	1.5	10
216	Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2740-2746.	2.3	10

#	ARTICLE	IF	CITATIONS
217	Higher hospital volume predicts endoscopy but not the in-hospital mortality rate in patients with acute variceal hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 221-229.	1.0	9
218	Improved Efficacy of Biological Maintenance Therapy in “Early” Compared With “Late” Crohn's Disease: Strike While the Iron Is Hot With Anti-TNF Agents?. <i>American Journal of Gastroenterology</i> , 2010, 105, 1583-1585.	0.4	9
219	Surgery for Crohn's disease: look harder, act faster. <i>Lancet</i> , The, 2015, 385, 1370-1371.	13.7	9
220	Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 561-568.	2.0	9
221	Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 203-204.	4.4	9
222	Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. <i>Future Microbiology</i> , 2021, 16, 1215-1227.	2.0	9
223	Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses’ Health Study cohorts. <i>Environmental Research</i> , 2022, 207, 112222.	7.5	9
224	Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5206-5212.	2.3	9
225	Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 225-233.	3.7	9
226	Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2012, 13, 472-477.	1.5	8
227	Estimating average treatment effects with a double-index propensity score. <i>Biometrics</i> , 2020, 76, 767-777.	1.4	8
228	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3548-3554.	2.3	8
229	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis</i> 360, 2020, 2, otaa039.	1.1	8
230	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2064-2071.e1.	4.4	8
231	Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 469-475.	1.9	8
232	Physician density and hospitalization for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 633-638.	1.9	7
233	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , 2018, 32, 31-37.	1.9	7
234	The Gut Microbiome and Digestive Health “A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 215-217.	4.4	7

#	ARTICLE	IF	CITATIONS
235	Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. Digestive Diseases and Sciences, 2020, 65, 3672-3678.	2.3	7
236	Impact of Diet on Risk of IBD. Crohn's & Colitis 360, 2020, 2, .	1.1	7
237	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	3.7	7
238	Length of Office Visits for Gastrointestinal Disease: Impact of Physician Specialty. American Journal of Gastroenterology, 2010, 105, 1719-1725.	0.4	6
239	Genetic risk factors for serious infections in inflammatory bowel diseases. Scandinavian Journal of Gastroenterology, 2017, 52, 570-576.	1.5	6
240	Tofacitinib: A Jak of All Trades. Clinical Gastroenterology and Hepatology, 2019, 17, 1438-1440.	4.4	6
241	Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2019, 13, 990-995.	1.3	6
242	IBD risk prediction using multi-ethnic polygenic risk scores. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 217-218.	17.8	6
243	Nutrition in the Management of Inflammatory Bowel Diseases. Gastroenterology Clinics of North America, 2021, 50, 151-167.	2.2	6
244	Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 303-313.e6.	4.4	6
245	Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. Clinical Gastroenterology and Hepatology, 2021, 19, 1108-1110.	4.4	6
246	Debate session: So what causes inflammatory bowel disease? It's all in the environment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 24-24.	2.8	5
247	Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. Inflammatory Bowel Diseases, 2022, 28, 1833-1837.	1.9	5
248	Clostridium difficile and inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1445-1446.	1.9	4
249	Toward reducing bias in clinical trials: central readers for endoscopic endpoints. Gastrointestinal Endoscopy, 2016, 83, 198-200.	1.0	4
250	Filgotinib for Crohn's disease—expanding treatment options. Lancet, The, 2017, 389, 228-229.	13.7	4
251	Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records data. Biometrics, 2021, 77, 413-423.	1.4	4
252	Clinical Research and Trials—A “Nonessential” Victim of the COVID-19 Pandemic?. American Journal of Gastroenterology, 2020, 115, 946-947.	0.4	4

#	ARTICLE	IF	CITATIONS
253	Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype. Clinical Gastroenterology and Hepatology, 2022, 20, 2347-2357.e14.	4.4	4
254	Patient Electronic Health Records as a Means to Approach Genetic Research in Gastroenterology. Gastroenterology, 2015, 149, 1134-1137.	1.3	3
255	CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. Digestive Diseases and Sciences, 2019, 64, 2265-2272.	2.3	3
256	Gastrointestinal Diseases. , 2020, , 16-26.		3
257	Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study. Inflammatory Bowel Diseases, 2021, 27, 476-481.	1.9	3
258	High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, , 1.	2.3	3
259	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.4	3
260	The Holy Grail, or Only Half Way There?. Gastroenterology, 2015, 148, 8-10.	1.3	2
261	Infliximab or ciclosporin for acute severe ulcerative colitis?. The Lancet Gastroenterology and Hepatology, 2016, 1, 2-3.	8.1	2
262	Use of Narrative Concepts in Electronic Health Records to Validate Associations Between Genetic Factors and Response to Treatment of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1890-1892.	4.4	2
263	Yield and Predictors of Surveillance Colonoscopies in Older Adults With Long-standing Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, e1353-e1364.	4.4	2
264	Antibiotic exposure is associated with development of inflammatory bowel disease. Journal of Pediatrics, 2013, 162, 1077.	1.8	1
265	The Toronto Consensus Guidelines for Nonhospitalized Ulcerative Colitis: A Welcome Update but Not the End of the Story. Gastroenterology, 2015, 148, 877-880.	1.3	1
266	Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions. Crohn's & Colitis 360, 2020, 2, otaa019.	1.1	1
267	Sa1836 FRAILITY AS A RISK FACTOR FOR HOSPITAL READMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE STUDY. Gastroenterology, 2020, 158, S-445-S-446.	1.3	1
268	Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools. New England Journal of Medicine, 2020, 382, 1042-1052.	27.0	1
269	Editorial: histologic normalisation in ulcerative colitis. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 401-401.	3.7	1
270	Management of Inflammatory Bowel Diseases: Clinical Perspectives. Clinical Gastroenterology and Hepatology, 2020, 18, 1249-1251.	4.4	1

#	ARTICLE	IF	CITATIONS
271	It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 446-447.	4.4	1
272	Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2021, 66, 733-737.	2.3	1
273	Plant-Based Diet Quality and Risk of Crohn's Disease and Ulcerative Colitis in US Women. <i>Current Developments in Nutrition</i> , 2021, 5, 462.	0.3	1
274	E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study. <i>Digestive Diseases and Sciences</i> , 2022, , .	2.3	1
275	Geographic variation and the incidence of inflammatory bowel disease among U.S. women. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S15.	1.9	0
276	Reply to Dr. McNabb-Baltar's letter. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 868.	1.3	0
277	P-056: Aryl Hydrocarbon Receptor Expression: A Comparison Between Patients with IBD and Healthy Controls, and Association with Serum Fatty Acids. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S49-S50.	1.9	0
278	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1577-1578.	4.4	0
279	Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 120-120.	3.7	0
280	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1703-1704.	4.4	0
281	P-014: Circulating C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S13-S14.	1.9	0
282	Editorial: co-existing immune-mediated disease in inflammatory bowel diseases – a new disease severity indicator? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1168-1168.	3.7	0
283	Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1026-1027.	3.7	0
284	Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1121-1121.	3.7	0
285	Bugs and drugs: Predicting response to therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 27-27.	2.8	0
286	Making sense of clinical predictors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 7-8.	2.8	0
287	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1177.	4.4	0
288	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1919.	4.4	0

#	ARTICLE	IF	CITATIONS
289	Patient age determines adherence to preventive care measures among patients with ulcerative colitis. Digestive and Liver Disease, 2019, 51, 178-179.	0.9	0
290	Reply. Gastroenterology, 2020, 159, 1993-1994.	1.3	0
291	Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 590-592.	1.9	0
292	Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 2021, , .	2.7	0
293	Frailty in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2021, 17, 263-268.	0.1	0
294	Issue Highlights. Clinical Gastroenterology and Hepatology, 2022, 20, 1195-1196.	4.4	0